Fresenius SE Total Liabilities and Share Holders Equity 2016-2023 | FSNUY
Fresenius SE total liabilities and share holders equity from 2016 to 2023. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- Fresenius SE total liabilities and share holders equity for the quarter ending September 30, 2023 was $81.987B, a 1.34% increase year-over-year.
- Fresenius SE total liabilities and share holders equity for 2022 was $80.511B, a 5.44% decline from 2021.
- Fresenius SE total liabilities and share holders equity for 2021 was $85.138B, a 11.83% increase from 2020.
- Fresenius SE total liabilities and share holders equity for 2020 was $76.13B, a 1.44% increase from 2019.
Fresenius SE Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2022 |
$80,511 |
| 2021 |
$85,138 |
| 2020 |
$76,130 |
| 2019 |
$75,047 |
| 2018 |
$66,966 |
| 2017 |
$60,056 |
| 2016 |
$51,398 |
| 2015 |
$47,936 |
Fresenius SE Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023-09-30 |
$81,987 |
| 2023-06-30 |
$83,321 |
| 2023-03-31 |
$82,172 |
| 2022-12-31 |
$80,511 |
| 2022-09-30 |
$80,906 |
| 2022-06-30 |
$80,998 |
| 2022-03-31 |
$82,049 |
| 2021-12-31 |
$85,138 |
| 2021-09-30 |
$83,819 |
| 2021-06-30 |
$83,927 |
| 2021-03-31 |
$83,145 |
| 2020-12-31 |
$76,130 |
| 2020-09-30 |
$79,867 |
| 2020-06-30 |
$76,586 |
| 2020-03-31 |
$76,090 |
| 2019-12-31 |
$75,047 |
| 2019-09-30 |
$74,236 |
| 2019-06-30 |
$72,980 |
| 2019-03-31 |
$73,810 |
| 2018-12-31 |
$66,966 |
| 2018-09-30 |
$64,789 |
| 2018-06-30 |
$65,572 |
| 2018-03-31 |
$65,765 |
| 2017-12-31 |
$60,056 |
| 2017-09-30 |
$62,405 |
| 2017-06-30 |
$58,181 |
| 2017-03-31 |
$57,993 |
| 2016-12-31 |
$51,398 |
| 2016-09-30 |
$48,773 |
| 2016-06-30 |
$49,500 |
| 2016-03-31 |
$46,825 |
| 2015-12-31 |
$47,936 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.379B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
